AIO-Studien-gGmbH

DSMB recommends continuing GOBLET study cohort 5 after safety review. Cohort 5 investigates pelareorep with mFOLFIRINOX, with/without atezolizumab, in newly diagnosed PDAC. Full trial updates expected in 2025.

Oncolytics Biotech reports DSMB recommendation for continued enrollment in GOBLET study Cohort 5, assessing pelareorep with modified FOLFIRINOX and atezolizumab for pancreatic ductal adenocarcinoma, pending PEI approval. Safety data expected in H1 2025, with initial efficacy results in H2.